Medical Technology segment of ZEISS

We improve the quality of life of patients and drive the progress, efficiency and access to healthcare.

ZEISS Medical Technology

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. In the field of microsurgery the company provides innovative visualization solutions.

With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations. ZEISS also offers visualization solutions for dental treatment and gynecology. The company's medical technology portfolio is completed by future-oriented technologies such as intraoperative radiotherapy.

Company overview

The Medical Technology activities of ZEISS are today largely bundled under the umbrella of the TecDAX-listed company Carl Zeiss Meditec AG in which Carl Zeiss AG holds ca. 59 percent interest.
Besides its headquarters in Jena/Germany, the Carl Zeiss Meditec AG has subsidiaries in the USA, Japan, Germany, Spain, France, Turkey and UK. Additional ZEISS Research and Development Centers in India and China strengthen the company's presence in these rapidly developing economies. In other countries the company makes use of the vaste distribution network of ZEISS.
Management board
Dr. Markus Weber (President and CEO)

Justus Felix Wehmer

The Carl Zeiss Meditec Group generated revenue of €1,646.8m in fiscal year 2020/21 (to 30 September).1
The Carl Zeiss Meditec Group has 3,531 employees worldwide, including around 400 at the headquarters in Jena (as of September 30, 2021).1

Social commitment at ZEISS Medical Technology

  • 20

    Physicians have been trained in the new training center

  • 10

    ICO fellows have been supported by ZEISS since 2021

  • 60

    Mobile screening stations are now available in India.

  • 1

    Revenue and Number of employees deviate from the published figures of the Medical Technology Segment of Carl Zeiss AG as a result of different consolidation models.